Biogen’s LEQEMBI Pen Gains Japanese Approval, Expanding Alzheimer’s Treatment Options — Biogen Inc.

Event summary

LEQEMBI Pen, a subcutaneous formulation of Biogen’s Alzheimer’s drug LEQEMBI, approved in Japan on September 16, 2026.
The autoinjector allows weekly at-home administration, reducing reliance on IV infusions in clinical settings.
Approval based on Phase 3 Clarity AD study data, showing comparable efficacy and safety to IV formulation.
LEQEMBI Pen is the third country to approve the subcutaneous formulation, following the U.S. and China.
Eisai leads global development and regulatory submissions, with co-commercialization by Eisai and Biogen.

The big picture

Biogen’s LEQEMBI Pen approval in Japan marks a strategic shift in Alzheimer’s treatment, offering a more flexible and patient-friendly administration method. This aligns with broader industry trends toward decentralized healthcare and home-based therapies, potentially reducing the burden on clinical resources. The approval also underscores the growing collaboration between Biogen and Eisai in advancing neurodegenerative disease treatments.

What we're watching

Market Expansion: Whether the Japanese approval will accelerate LEQEMBI Pen’s adoption in other global markets.
Patient Compliance: How the convenience of at-home administration will impact patient adherence and treatment outcomes.
Regulatory Dynamics: The pace at which additional countries approve the subcutaneous formulation, broadening LEQEMBI’s reach.